Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Henry

Showing results (621-630 of 732) with videos related to

Pageof 74
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
Neurourology and Urodynamics|September 6, 2022
Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)Kathryn E Flynn, Jonathan B Wiseman, Margaret E Helmuth, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 6, 2019
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized studyH Henry Li, Bruce Zuraw, Hilary J Longhurst, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 26, 2019
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized StudyWilliam R Lumry, Inmaculada Martinez-Saguer, William H Yang, et al.
Nature Communications|February 15, 2018
Toward a consistent modeling framework to assess multi-sectoral climate impactsErwan Monier, Sergey Paltsev, Andrei Sokolov, et al.
The Journal of Biological Chemistry|October 22, 2004
The poxvirus p28 virulence factor is an E3 ubiquitin ligaseJianing Huang, Qi Huang, Xiulan Zhou, et al.
The Journal of Urology|January 17, 2023
Risk Factors for Increased Stent-associated Symptoms Following Ureteroscopy for Urinary Stones: Results From STENTSJonathan D Harper, Alana C Desai, Naim M Maalouf, et al.
Journal of Endourology|October 21, 2020
Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study DesignCharles D Scales, H Henry Lai, Alana C Desai, et al.
BMC Urology|April 7, 2022
Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTSJonathan D Harper, Alana C Desai, Jodi A Antonelli, et al.
Pageof 74

Showing results (621-630 of 732) with videos related to

Sort By:
Pageof 74
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
Neurourology and Urodynamics|September 6, 2022
Comparing clinical bladder diaries and recalled patient reports for measuring lower urinary tract symptoms in the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN)Kathryn E Flynn, Jonathan B Wiseman, Margaret E Helmuth, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|September 6, 2019
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized studyH Henry Li, Bruce Zuraw, Hilary J Longhurst, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 26, 2019
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized StudyWilliam R Lumry, Inmaculada Martinez-Saguer, William H Yang, et al.
Nature Communications|February 15, 2018
Toward a consistent modeling framework to assess multi-sectoral climate impactsErwan Monier, Sergey Paltsev, Andrei Sokolov, et al.
The Journal of Biological Chemistry|October 22, 2004
The poxvirus p28 virulence factor is an E3 ubiquitin ligaseJianing Huang, Qi Huang, Xiulan Zhou, et al.
The Journal of Urology|January 17, 2023
Risk Factors for Increased Stent-associated Symptoms Following Ureteroscopy for Urinary Stones: Results From STENTSJonathan D Harper, Alana C Desai, Naim M Maalouf, et al.
Journal of Endourology|October 21, 2020
Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study DesignCharles D Scales, H Henry Lai, Alana C Desai, et al.
BMC Urology|April 7, 2022
Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTSJonathan D Harper, Alana C Desai, Jodi A Antonelli, et al.
Pageof 74